“Toxicity studies were conducted in a single species, i.e. cynomolgus monkeys, based on comparable binding affinity and functional activity of teprotumumab to human and cynomolgus IGF-1R and lack of reactivity with rodent IGF-1R.”
Comparable binding affinity and functional activity at human and cynomolgus IGF-1R; no reactivity with rodent IGF-1R
“Toxicity studies were conducted in a single species, i.e. cynomolgus monkeys, based on comparable binding affinity and functional activity of teprotumumab to human and cynomolgus IGF-1R and lack of reactivity with rodent IGF-1R.”
No surrogate; the clinical antibody was tested in cynomolgus monkeys
“Toxicity studies were conducted in a single species, i.e. cynomolgus monkeys, based on comparable binding affinity and functional activity of teprotumumab to human and cynomolgus IGF-1R and lack of reactivity with rodent IGF-1R.”
“Toxicity studies were conducted in a single species, i.e. cynomolgus monkeys, based on comparable binding affinity and functional activity of teprotumumab to human and cynomolgus IGF-1R and lack of reactivity with rodent IGF-1R.”
Cynomolgus monkey (non-GLP embryo-fetal dose range-finding study only)
“The nonclinical program consisted primarily of primary and safety pharmacology studies, intravenous toxicity studies in monkeys (up to 39 weeks), and a non-GLP embryo-fetal dose range-finding study in monkeys.”
✓ VerifiedFDA pharmacology/toxicology review, p. 13Source ↗
Species: carcinogenicity
Not conducted (ICH S6(R1))
“No carcinogenicity studies were conducted. In line with ICH S6(R1), this is acceptable.”
“Toxicity studies were conducted in a single species, i.e. cynomolgus monkeys, based on comparable binding affinity and functional activity of teprotumumab to human and cynomolgus IGF-1R and lack of reactivity with rodent IGF-1R.”